Pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus)

Unicycive announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and certain other Asian markets

September 4, 2019, a pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus) has been held at the Drug Evaluation Center (CDE) of NMPA. CDE representatives include Zhou Ming (Major reviewer), Song Yuanyuan, Xia Lin, Chen Dongmei, Zhang Qian and others. Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd. representatives include Dr. Benjamin Li, Michael Wong, Hande Ping, Li Yujie, Liu Jianfeng, Li Peizhi, Du Yifan.

ดาวน์โหลดข่าวฉบับเต็ม (PDF)

ที่มา: Lee’s Pharmaceutical Holdings – News & Media

ข่าวสารอื่นๆ

thThai